Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis

European Neurology

Volumn 73, Issue 3-4, 2015, Pages 220-229

  Cobo Calvo, Álvaro ^a   Bau, Laura ^a   Matas, Elisabet ^a   Romero Pinel, Lucía ^a   Mañé Martínez, M Alba ^a,c   Majós, Carles ^b   Martínez Yélamos, Sergio ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Disease activity; Multiple sclerosis; Natalizumab; Predictors; Prognosis

Indexed keywords

CLADRIBINE; GADOLINIUM; GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ERYTHEMA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE INFECTION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; TREATMENT OUTCOME;

EID: 84925431283     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000375371     Document Type: Article

References (25)

1. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
3. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R: Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260.
4. Havrdova E, Galetta S, Stefoski D, Comi G: Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(suppl 3):S3-S7.
5. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators: Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190-1197.
6. Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C: Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 2012; 323: 104-112.
7. Melin A, Outteryck O, Collongues N, Zéphir H, Fleury MC, Blanc F, Lacour A, Ongagna JC, Berteloot AS, Vermersch P, de Sèze J: Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 2012; 259: 1215-1221.
8. Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X: Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 2012; 259: 1814-1823.
9. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V: Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-37.
10. Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LM, Ghezzi A, Martinelli V, Comi G: Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a postmarketing observational study. Neurol Sci 2011; 31(suppl 3):S299-S302.
11. Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M: Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 240-245.
12. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators: The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256: 405-415.
13. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS: Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-423.
14. Havrdová E, Bates D, Galetta S, Giovannoni G, Hutchinson M, Lublin FD, Pellegrini F, Phillips J, Polman C, Wiendl H, Belachew S, Patel R, Pace A: Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (poster 519). 29th Congress of the ECTRIMS, 2013.
15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mc-Donald criteria. Ann Neurol 2011; 69: 292-302.
17. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ: EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-676.
18. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P: MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491-1498.
19. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE: Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011; 17: 970-979.
20. Wiendl H, Butzkueven H, Kappos L, Pellegrini F, Trojano M, Paes D, et al: Disease activity and disability progression decrease beyond 2 years on natalizumab in relapsing MS patients in the TYSABRI ® (natalizumab) observational program (poster 1050). 29th Congress of the ECTRIMS, 2013.
21. Frequin ST, Barkhof F, Lamers KJ, Hommes OR: The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. J Neuroimmunol 1992; 40: 265-272.
22. Burnham JA, Wright RR, Dreisbach J, Murray RS: The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41: 1349-1354.
23. Mäurer M, Wiendl H, Heesen C, Gass A, Wernsdörfer C, Wettmarshausen C, Zingler V, Kieseier BC: Long-term therapy with natalizumab in clinical routine: final results of the observational program TYSABRI ® 24 PLUS (poster 376). 23rd meeting of the ENS, 2013.
24. Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J: Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler 2011; 17: 16-23.
25. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.